IngenOx Therapeutics

Spun out of parent company Celleron Therapeutics Ltd and armed with €37m from a series A financing, SynOx Therapeutics is advancing a cancer drug that was on the shelf at Roche Holding AG for th

Venture capital investment in US biopharmaceutical companies slowed in early July as Americans dealt with the awkwardness of celebrating a national holiday right in the middle of the work week by taki

Phase I clinical studies of Prokarium 's two novel oral thermostable vaccines, against enteric fever (typhoid plus paratyphoid) and plague, are expected to start in 2019, says Ted Fjallman, CEO of th

Quintiles has invested £3 million in a new company formed in partnership with the University of Oxford and two of its professors, which will provide oncology consulting services and new cancer biomark